FDA committees to review COX-2 inhibitor risk-benefit profile.

Reports on the plan of the U.S. Food and Drug Administration Arthritis Drugs and Drug Safety and Risk Management Advisory committees to review the risk-benefit profile of COX-2. Gastrointestinal protective claims in COX-2 labeling; Pressure to review cardiovascular effect of COX-2.